Novo Nordisk partners with OpenAI in weight loss drug race
Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, is partnering with OpenAI to deploy the technology…
Novo Nordisk cuts sales and profits guidance amid obesity drug competition
The drugmaker behind Ozempic and Wegovy has cut its sales and profit targets in the face of intense…
Novo Shares Tumble on Forecast for Steep Drop in Sales
(Bloomberg) — Novo Nordisk A/S shares plunged after the company shocked investors by forecasting a steep decline in…
Sales warning slams Ozempic maker Novo Nordisk’s stock
Novo Nordisk chief Mike Doustdar expects a pill version of the weight-loss drug Wegovy to get European approval…
Novo Nordisk sues Hims for GLP-1 patent infringement
[Adobe Stock] Imitation is the sincerest form of flattery, some say. Novo Nordisk would probably disagree. Copycats of…
Sales warning slams Ozempic maker Novo Nordisk’s stock
Novo Nordisk chief Mike Doustdar expects a pill version of the weight-loss drug Wegovy to get European approval…
Novo Nordisk A/S Q4 Earnings Call Highlights
Novo Nordisk A/S logo Novo expects a top-line decline of 5%–13% for 2026, attributing the outlook to “extraordinary…